Ubs Group Ag Aerovate Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 6,344 shares of AVTE stock, worth $16,240. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,344

Previous 11,052 42.6%

Holding current value

$16,240

Previous $18,000 27.78%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.61 - $2.09 $7,579 - $9,839	-4,708 Reduced 42.6%	6,344 $13,000
Q2 2024 Aug 13, 2024	SELL	$1.41 - $30.75 $260 - $5,688	-185 Reduced 1.65%	11,052 $18,000
Q1 2024 May 13, 2024	SELL	$17.68 - $29.57 $17,750 - $29,688	-1,004 Reduced 8.2%	11,237 $332,000
Q4 2023 Feb 09, 2024	BUY	$9.58 - $24.25 $9,838 - $24,904	1,027 Added 9.16%	12,241 $277,000
Q3 2023 Nov 09, 2023	BUY	$12.9 - $18.88 $105,973 - $155,099	8,215 Added 273.92%	11,214 $152,000
Q2 2023 Aug 11, 2023	SELL	$15.63 - $22.01 $46,686 - $65,743	-2,987 Reduced 49.9%	2,999 $51,000
Q1 2023 May 12, 2023	BUY	$19.17 - $27.7 $114,751 - $165,812	5,986 New	5,986 $120,000
Q3 2022 Nov 10, 2022	BUY	$14.77 - $25.79 $23,809 - $41,573	1,612 New	1,612 $26,000
Q1 2022 May 16, 2022	SELL	$8.25 - $18.33 $3,993 - $8,871	-484 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$9.14 - $21.54 $5,547 - $13,074	-607 Reduced 55.64%	484 $6,000
Q3 2021 Nov 15, 2021	SELL	$11.76 - $22.49 $11,277 - $21,567	-959 Reduced 46.78%	1,091 $23,000
Q2 2021 Aug 13, 2021	BUY	$22.83 - $22.83 $46,801 - $46,801	2,050 New	2,050 $47,000

Others Institutions Holding AVTE

# of Institutions

Shares Held

28.1M

Call Options Held

116K

Put Options Held

26.6K

View Full List

About Aerovate Therapeutics, Inc.

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $62.6M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

More about AVTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account